Strand Therapeutics
 United States
                                                 -                                                 Cambridge, Massachusetts
                                                                                                                                    
                                                                                                United States
                                                 -                                                 Cambridge, Massachusetts
                                                                                            
                                                                                    - 15/12/2022
- Series A
- $97,000,000
Strand  was  started  by  biological  engineers  working  together  at  MIT.  Building  on  the  idea  of  creating smart  therapies  that  are  capable  of  making  sophisticated  decisions,  they  sought  to  apply  the  concept of  the  emerging  field  of  mRNA  therapeutics.  This  area  was  untapped  by  traditional  synthetic  biology, which  led  them  to  build  their  own  mRNA  “programming  language,”  creating  the  world’s  first  platform for  mRNA  smart  therapies.  
Strand’s  mRNA  programming  technology  promises  to  make  mRNA  therapies safer  and  more  effective  by  programming  the  location,  timing,  and  intensity  of  therapeutic  protein  expression inside  a  patient’s  body  using  mRNA-encoded  logic  circuits.  These  circuits  can  implement  cell-type specific  expression  by  sensing  and  classifying  the  unique  miRNA  expression  signatures  of  cells,  as  well as  controlling  the  dosage  of  protein  expression  by  responding  to  exogenously administered  small  molecules.
- Industry Biotechnology Research
- Website https://www.strandtx.com/
- LinkedIn https://www.linkedin.com/company/strandtx/
Related People
Jacob BecraftCo Founder
 United States -
                                                         Cambridge, Massachusetts,
                                                    
                                                                                                                United States -
                                                         Cambridge, Massachusetts,
                                                    
                                                Jake Becraft is a synthetic biologist and biotech entrepreneur, as well as the co-founder and CEO of Strand Therapeutics. Strand is situated at the intersection of synthetic biology, immunotherapy, and mRNA therapeutics. Jake started his career developing the SAfER platform at MIT, the world’s first synthetic biology programming language for mRNA. Beyond that work, his broader interests span synthetic biology, the intersection of hard-tech and biologically engineered therapeutics, and biologically engineered organism-machine interfaces. He is an inventor on a multitude of patents in the biotech/gene therapy space and has won numerous awards for his scientific and entrepreneurial achievements, including a Goldwater Scholarship, a Viterbi Fellowship, and an Amgen fellowship. He is an advocate among the life science entrepreneurial ecosystem for supporting founder-driven biotech startups and works to help increase young technical founders in biotech entrepreneurship. Jake has previously served as a Science and Technology advisor to legislators in the Massachusetts State Legislature. He often speaks internationally on the field of synthetic biology, as well as the broader entrepreneurship environment necessary to bring next generation synbio gene therapeutics to market. Jake also serves on the Executive Board of Public Health United, a non-profit focused on educating scientists across disciplines to foster their communication skills in order to become their own scientific ambassadors. He received his PhD in Biological Engineering and Synthetic Biology from MIT and his BS in Chemical and Biomolecular Engineering from the University of Illinois at Urbana-Champaign, graduating Magna cum Laude with distinction. In his free time, he is an avid back-country snowboarder and trains Brazilian Jiu-Jitsu.
 Vesence |  $9,000,000  | (Oct 30, 2025)
                                Vesence |  $9,000,000  | (Oct 30, 2025) Sparrow BioAcoustics |  $10,000,000  | (Oct 30, 2025)
                                Sparrow BioAcoustics |  $10,000,000  | (Oct 30, 2025) 
                             Reflectiz |  $22,000,000  | (Oct 30, 2025)
                                Reflectiz |  $22,000,000  | (Oct 30, 2025) 
                             
                                     
                                     
                                     
                                     
                                     
                                             
                                                 
                                                     
                                                     
                                                     
                                                     
                                                 
                                                     
                                                 
                                                     
                                                 
                                                     
                                                 
                                                     
                                                 
                                                 
                                                 
                                                 
                                                 
                                                     Mem0 |  $24,000,000  | (Oct 30, 2025)
                                                                        
                                Mem0 |  $24,000,000  | (Oct 30, 2025) Valthos |  $30,000,000  | (Oct 30, 2025)
                                                                        
                                Valthos |  $30,000,000  | (Oct 30, 2025) Mondra |  $13,206,500  | (Oct 30, 2025)
                                                                        
                                Mondra |  $13,206,500  | (Oct 30, 2025) hoop.dev |  Undisclosed Amount  | (Oct 30, 2025)
                                                                        
                                hoop.dev |  Undisclosed Amount  | (Oct 30, 2025) IORGANBIO |  $2,000,000  | (Oct 30, 2025)
                                                                        
                                IORGANBIO |  $2,000,000  | (Oct 30, 2025) FrontlineIQ |  $3,300,000  | (Oct 30, 2025)
                                                                        
                                FrontlineIQ |  $3,300,000  | (Oct 30, 2025) Homecourt |  $8,000,000  | (Oct 30, 2025)
                                                                        
                                Homecourt |  $8,000,000  | (Oct 30, 2025) VentureMed Inc. |  $28,000,000  | (Oct 30, 2025)
                                                                        
                                VentureMed Inc. |  $28,000,000  | (Oct 30, 2025) Recess |  $30,000,000  | (Oct 30, 2025)
                                                                        
                                Recess |  $30,000,000  | (Oct 30, 2025)